Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin + AVD in pediatric Hodgkin lymphoma
NCT02979522Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- Sep 2017
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of brentuximab vedotin in Hodgkin lymphoma (HL) (2 arms), sponsored by Takeda. Primary endpoints: Recommended Dose of Brentuximab Vedotin in Combination With Doxorubicin, Vinblastine, and Dacarbazine at 56 days, Adverse Events and 6 more. Started Sep 2017; status: active, not recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02979522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02979522.